Menu
Search
|

Menu

Close
X

Regenxbio Inc RGNX.OQ (NASDAQ Stock Exchange Global Select Market)

47.74 USD
+0.78 (+1.66%)
As of Jul 17
Previous Close 46.96
Open 46.96
Volume 132,107
3m Avg Volume 188,630
Today’s High 48.70
Today’s Low 46.87
52 Week High 83.35
52 Week Low 38.64
Shares Outstanding (mil) 36.64
Market Capitalization (mil) 1,720.46
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.33 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY19
1
FY18
219
FY17
10
FY16
5
EPS (USD)
FY19
-0.886
FY18
2.887
FY17
-2.479
FY16
-2.383
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.16
Price to Sales (TTM)
vs sector
19.78
8.16
Price to Book (MRQ)
vs sector
3.53
4.38
Price to Cash Flow (TTM)
vs sector
--
24.12
Total Debt to Equity (MRQ)
vs sector
0.00
18.17
LT Debt to Equity (MRQ)
vs sector
0.00
13.01
Return on Investment (TTM)
vs sector
-9.13
12.64
Return on Equity (TTM)
vs sector
-9.29
17.19

EXECUTIVE LEADERSHIP

Donald Hayden
Independent Chairman of the Board, Since 2016
Salary: --
Bonus: --
Kenneth Mills
President, Chief Executive Officer, Executive Director, Since 2009
Salary: $546,364.00
Bonus: --
Vittal Vasista
Chief Financial Officer, Since 2017
Salary: $379,300.00
Bonus: --
Curran Simpson
Senior Vice President - Product Development, Chief Technology Officer, Since 2018
Salary: $371,300.00
Bonus: --
Patrick Christmas
Senior Vice President, General Counsel, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

9600 Blackwell Rd Ste 210
ROCKVILLE   MD   20850-3655

Phone: +1240.5528181

REGENXBIO Inc. is a clinical-stage biotechnology company. The Company's gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases. Its product candidate, RGX-314, is meant for the treatment of wet age-related macular degeneration (wet AMD). Its product candidate, RGX-501, is meant for the treatment of homozygous familial hypercholesterolemia (HoFH). It is also developing product candidates, such as RGX-111 and RGX-121, to address the neurological symptoms of two severe genetic lysosomal storage diseases, Mucopolysaccharidosis Type I (MPS I) and Mucopolysaccharidosis Type II (MPS II), respectively. Its product candidates utilize viral vectors from its gene delivery platform, NAV Technology Platform.

SPONSORED STORIES